IL33 and myeloid sarcoma: Several studies reported the involvement of IL-33/ST2 signaling in the pathogenesis of Alzheimer’s disease (AD) [68], multiple sclerosis (MS) [69], experimental autoimmune encephalomyelitis [70], experimental cerebral malaria (ECM) [71], chronic pain [72], intracranial hemorrhage (ICH) [73], and stroke [74].